Clinical trial
A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study 05-06 of Groupe Français de Pneumo-Cancérologie (GFPC).
NCT00284778 is registered in ClinicalTrials.gov with University Hospital, Limoges as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study 05-06 of Groupe Français de Pneumo-Cancérologie (GFPC).
- Lead sponsor
- University Hospital, Limoges
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2006
- Completion date
- December 31, 2009
- Enrollment
- 150 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.